Evotec SE Share Price

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra 16:35:04 31/05/2024 BST 5-day change 1st Jan Change
8.655 EUR +3.04% Intraday chart for Evotec SE -2.15% -59.33%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 881M 957M 75.07B Sales 2025 * 1.04B 1.13B 88.3B Capitalization 1.53B 1.67B 131B
Net income 2024 * -27M -29.31M -2.3B Net income 2025 * 32M 34.74M 2.73B EV / Sales 2024 * 2.05 x
Net Debt 2024 * 269M 292M 22.91B Net Debt 2025 * 235M 255M 20.02B EV / Sales 2025 * 1.71 x
P/E ratio 2024 *
-58.3 x
P/E ratio 2025 *
32.3 x
Employees 5,055
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.64%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.04%
1 week-2.15%
1 month-12.53%
3 months-37.93%
6 months-52.99%
Current year-59.33%
More quotes
1 week
8.28
Extreme 8.275
9.32
1 month
8.28
Extreme 8.275
10.66
Current year
8.28
Extreme 8.275
21.42
1 year
8.28
Extreme 8.275
24.44
3 years
8.28
Extreme 8.275
45.83
5 years
8.28
Extreme 8.275
45.83
10 years
2.42
Extreme 2.42
45.83
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 18/06/19
Director of Finance/CFO 51 06/02/23
Chief Operating Officer 54 30/04/12
Members of the board TitleAgeSince
Chief Executive Officer 61 18/06/19
Director/Board Member 56 18/06/19
Chairman 63 16/06/14
More insiders
Date Price Change Volume
31/05/24 8.655 +3.04% 1,311,590
30/05/24 8.4 -1.12% 1,479,396
29/05/24 8.495 -5.98% 2,116,503
28/05/24 9.035 -1.58% 1,393,505
27/05/24 9.18 +3.79% 915,736

Delayed Quote Xetra, May 31, 2024 at 04:35 pm

More quotes
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.655 EUR
Average target price
20.79 EUR
Spread / Average Target
+140.21%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW